Section 1 Short title
This Act may be cited as the “Medicare IVIG Access Enhancement Act of 2023”.
Medicare IVIG Access Enhancement Act of 2023
A BILL
To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.
Sec. 2 Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program
in subsection (s)(2)(Z), by inserting “(and, beginning January 1, 2026, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency diseases”; and
in subsection (zz), by inserting “(or, beginning January 1, 2026, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency disease”.
Authority for variance in payments— Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting “and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)” after “of 2012”.